67 results about "C57BL/6" patented technology

The invention discloses an application of bulbus lilii glycoside B. The application is that bulbus lilii glycoside B is used as a unique active component or one of the active components to prepare a product for preventing or / and treating skin photoaging diseases. Experimental results of the invention show that lilium brownii glycoside B can significantly improve the cell viability of UVA-induced human skin fibroblasts, can reduce the number of beta-galactosidase positive cells in the UVA-induced human skin fibroblasts and reduce lipofuscin deposition, and can significantly improve the photoaging of the UVA-induced skin fibroblasts. Meanwhile, the skin photoaging grading of the back of a C57BL / 6 mouse induced by UVA can be remarkably improved. Therefore, the bulbus lilii glycoside B is expected to be used as an active ingredient for preparing medicines or cosmetics for preventing or / and treating the skin photoaging diseases, and particularly has important significance and remarkable application value for preventing or / and treating the UVA-induced skin photoaging diseases.

The present application provides a mouse model for studying microsatellite stable and unstable intestinal cancer. Specifically, the present application provides the use of a hybrid mouse in a reagent or kit for preparing a mouse model animal for constructing MSS type intestinal cancer and MSI-H type intestinal cancer, wherein the mouse is a F1 generation of C57BL / 6 x BALB / c. The mouse model of the present application provides the same genetic background for MSS type intestinal cancer cells and MSI-H type intestinal cancer cells, making the research of MSS type intestinal cancer and MSI-H type intestinal cancer more scientific.

This invention provides a method for constructing a fluorescently traced mouse model and its application in the sorting of Mcpt4-positive and negative mast cells. First, the Cre gene is knocked into the Mcpt4 gene sequence of C57BL / 6 mice using CRISPR / Cas9 technology. Then, through animal hybridization and Cre-loxP recombination technology, a fluorescently traced mouse model of Mcpt4-positive mast cells is obtained. The fluorescently traced mouse model possesses a dual-fluorescent reporter gene system consisting of the red fluorescent protein tdTomato and the green fluorescent protein ZsGreen. Mcpt4-positive mast cells exhibit red fluorescence, while other Mcpt4-negative cells exhibit green fluorescence. Using this fluorescently traced mouse model, Mcpt4-positive and negative mast cells can be rapidly, accurately, and effectively sorted, providing a reliable technical basis for exploring the roles and mechanisms of Mcpt4-positive and negative mast cells in immune responses.

The invention discloses an application of senkyunolide I in preparation of a medicine for treating hepatic fibrosis, which can obviously inhibit HSC (hepatic stellate cell) activation in vitro and evaluate the treatment effect of senkyunolide I on hepatic fibrosis in vivo by adopting a C57BL / 6 mouse hepatic fibrosis model induced by CCl4. The expression levels of liver alpha-smooth muscle actin, type I collagen and matrix metalloproteinase tissue inhibition factor 1 of individuals needing anti-hepatic fibrosis are obviously reduced in vivo and in vitro, and the hepatic fibrosis progress can be effectively intervened. Therefore, according to the application of the senkyunolide I in the hepatic fibrosis, the provided compound senkyunolide I has huge potential for inhibiting the hepatic fibrosis, an effective traditional Chinese medicine monomer component medicine is provided for treating the hepatic fibrosis, the new clinical adaptation application of the senkyunolide I is expanded, and the application prospect is good.

The application belongs to the technical field of biotechnology, and particularly relates to a colorectal cancer high liver metastasis cell line and a preparation method and application thereof. The cell line was preserved in the China Center for Type Culture Collection on January 14, 2026, and the preservation number is CCTCC NO: C202618. The cell line is derived from a mouse colorectal cancer cell line MC38, and is constructed by lentivirus transfection to express luciferase stably, and is obtained by continuously performing at least five rounds of liver metastasis tumor orthotopic iteration screening in C57BL / 6 mice through rectal submucosal injection. The MC38-P06 cell line provided by the application has a significantly enhanced liver metastasis ability, a shorter MC38-P01 model time, a higher liver tumor load, and a shorter mouse survival period, and can be used for screening and evaluating anti-liver metastasis drugs, researching liver microenvironment regulation mechanisms, and identifying liver metastasis related diagnostic markers.

The invention relates to an application of an aureomycin A derivative in preparation of an anti-tumor drug, the anti-tumor drug is a drug for preventing or treating liver cancer, and the aureomycin A derivative is selected from a compound shown as a formula (I), or a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a pharmaceutically acceptable ester or a pharmaceutically acceptable solvate of the compound. The aureomycin A derivative disclosed by the invention can be used for remarkably inhibiting the proliferation of liver cancer cells Hepa1-6, and the half inhibitory concentration (IC50 value) is 0.4821 mu g / mL and 0.1701 mu g / mL respectively; 11 days after administration, the tumor volume of a Hepa1-6 ectopic transplantation C57BL / 6 mouse is reduced, and the tumor weight of a Hepa1-6 tumor ectopic transplantation tumor is reduced; the aureomycin A derivative has the effects of remarkably inhibiting proliferation of liver cancer cells at the cellular level and remarkably reducing tumor growth of the liver cancer cells at the animal level, and a research direction is provided for development of new drugs.

The invention relates to application of lactobacillus muricatum in preparation of a medicine for treating oral cancer, the oral cancer is oral squamous cell carcinoma, a C57BL / 6 mouse tongue squamous cell carcinoma model induced by a 4-NQO water drinking method and a C3H / HeN subcutaneous tumor model inoculated by SCC7 tumor cells are constructed, and the lactobacillus muricatum has a remarkable inhibition effect on the oral cancer; experiments prove that the number / area / volume / weight of tumors is remarkably reduced by the lactobacillus muricatum, tumor marginal infiltration and abnormal karyokinesis are effectively inhibited, the expression quantity of tumor proliferation markers is remarkably reduced, and obvious pathological changes do not appear in main organs (heart, liver, spleen, lung and kidney) of mice. The method for minimally invasive injection of the lactobacillus muricatum into the oral squamous cell cancer tumor is safe, drug resistance is not easily induced, the treatment scheme is standardized, and the method has good clinical application potential.

The invention discloses an application of a SUMO agonist N106 (the molecular formula is C17H14N4O3S, and the molecular weight is 354.38) in treatment or prevention of metabolic dysfunction related fatty liver disease (MASLD). The early-stage research of the invention finds that the liver SUMOylation level in MASLD clinical specimens and animal models is significantly reduced. In-vivo experiments show that in a high-fat diet induced C57BL / 6 mouse model, N106 (10mg / kg, intraperitoneal injection, once a day) can significantly improve liver lipid deposition and blood fat level of a high-fat diet mouse; in in-vitro experiments, N106 (10 mu M for 24 hours) can effectively reduce lipid droplet accumulation of HepG2 cells. The research reveals that N106 regulates lipid metabolism by activating an SUMOylation modification pathway for the first time, and a novel treatment strategy is provided for MASLD.

Embodiments of the present invention relate to the technical field of cell reprogramming, and disclose a reprogramming culture medium and a method for reprogramming chinchilla somatic cells into pluripotent stem cells. Among them, the culture medium includes culture medium I and culture medium II; culture medium I is a DMEM culture medium containing ≥5 v / v% serum substitute, ≥0.2 v / v% Nucleosides, ≥0.2 v / v% GlutaMax, 0.1 mM - 10.0 mM NEAA, 0.02 mM - 1 mM 2-mercaptoethanol, 1000 - 3000 U / mL LIF, 0.3 μM - 10 μM PD0325901, and 1 μM - 10 μM CHIR-99021; culture medium II is a complete culture medium for C57BL / 6 mouse embryonic stem cells. The method includes: reprogramming chinchilla somatic cells by transfecting transcription factors, and culturing the reprogrammed chinchilla somatic cells with culture medium I and culture medium II in sequence after transfection. By applying the technical solution of the present invention, chinchilla IPSCs can be successfully obtained.

The invention provides an anti-leukemia pharmaceutical composition based on DNA damage activated NKT cells and application of the anti-leukemia pharmaceutical composition. A mouse leukemia model is adopted as a research object, and experimental results show that in a C1498 homotransplantation tumor C57BL / 6 immune sound mouse leukemia model, the tumor inhibition rate of a daunorubicin and alpha-galactosylceramide combined treatment group reaches 67.4%, the survival time is remarkably prolonged, and obvious toxicity is not caused; in a C57 mouse leukemia model constructed by caudal vein injection of C1498, daunorubicin and alpha-galactosylceramide are combined to treat and reverse leukemia-related hepatosplenomegaly (the weight of liver and spleen is equivalent to that of a normal group), leukocyte proliferation is inhibited, and the survival state of mice is improved. The invention provides a new direction for treatment of leukemia.

The present invention belongs to the field of biomedical technology, and discloses the application of putrescine in the preparation of a drug for preventing and treating OHSS. Starting from the pathological mechanism of OHSS, an OHSS model was established with C57BL / 6 female mice, and putrescine was given through natural drinking water to explore its preventive and therapeutic effects on OHSS. The results showed that putrescine could reduce the ovarian weight, ovarian somatic ratio, number of congested follicles, number of corpora lutea, and VEGF expression level in the OHSS model, and would not have an adverse effect on the litter size of mice, indicating that putrescine can effectively prevent and treat OHSS. The present invention predicts to provide a new intervention approach and candidate drug for the clinical prevention of OHSS.

This invention belongs to the field of tumor biology and drug screening technology, specifically disclosing a human EGFR mutation-driven mouse primary lung cancer cell line, its construction method, and its applications. The cell line, ZST-1, is a human EGFR (L858R / T790M) mutation-driven lung cancer cell line derived from mouse primary lung cancer. It is stable, capable of subcutaneous tumor formation in C57BL / 6 mice, and simultaneously expresses Luciferase and tdTomato reporter genes. Its construction method includes obtaining transgenic mice, virus-induced tumor formation, continuous in vivo passage in nude mice, and in vitro culture and screening steps. This cell line can be applied to in vitro screening and efficacy evaluation of human EGFR mutation-targeting drugs, research on EGFR-TKI resistance mechanisms, tumor bioluminescence imaging and fluorescence tracing, and in vivo tumorigenesis and efficacy experiments in an immune-intact C57BL / 6 background.

The invention discloses a high-efficiency C57BL / 6 mouse in-vitro fertilization method, relates to use of an in-vitro fertilization method in the technical field of biology, and particularly relates to a method for obtaining more high-quality fertilized eggs for gene editing in an in-vitro fertilization process of small animal gene editing model construction. Therefore, the animal cost of gene editing is greatly reduced, and wide application is promoted.

The invention discloses application of apolipoprotein H in preparation of drugs or health care products for preventing and / or treating alcoholic diseases. Researches show that an alcoholic hepatitis model is constructed by taking 10-week-old ApoH gene knockout mice (C57BL / 6ApoH- / -) as a background, a wild C57BL / 6 mouse alcoholic hepatitis model is taken as a contrast, peripheral blood transaminase and blood fat level, liver tissue fat content and liver tissue immunohistochemical staining are detected, and a result shows that the TC content of the liver tissue of the ApoH- / -mouse is obviously increased. The composition and content of bile acid in liver tissues and intestinal contents and the composition and abundance of intestinal flora are further detected, and results indicate that metabolic disorder of bile acid and disorder of intestinal flora exist. Based on the mechanism that low expression of alcoholic apolipoprotein H causes disorder of intestinal flora, affects bile acid metabolism and aggravates hepatic cell adiposis, the application is an accurate targeted therapeutic drug for treating alcoholic multi-organ injury.

The present invention discloses an application of a PAI-1 inhibitor in the preparation of a drug for treating liver ischemia-reperfusion injury, and relates to the field of biomedicine technology. The present invention selects PAI-1 gene knockout mice and C57BL / 6 wild-type mice as experimental subjects, constructs mouse liver ischemia-reperfusion injury models respectively, and studies the function of PAI-1 in liver ischemia-reperfusion injury. The study found that after PAI-1 knockout, it can reduce liver ischemia-reperfusion injury by affecting the formation and recruitment of liver neutrophil induction network, inhibiting the inflammatory response of the liver. PAI-1 is a key gene that affects neutrophil activation and is an important target for regulating inflammatory response during the reperfusion period. Animal experiments have verified that the PAI-1 specific inhibitor PAI-039 can reduce the degree of injury of mouse liver ischemia-reperfusion, providing new ideas for the development of new drugs for preventing, alleviating and / or treating tissue ischemia-reperfusion injury.

The invention relates to application of tectoridin in preparation of a medicine for treating radiation-induced lung injury. According to the invention, the influence of tectoridin on radiation-induced lung injury is researched by constructing a C57BL / 6 mouse radiation-induced lung injury model; research results prove that the exogenous irisin can relieve alveolar interstitial thickening, hyperemia, pulmonary edema, alveolar collapse, airway wall thickening, airway cavity narrowing and increase of collagen deposition around the airway caused by radiation; besides, the tectoridin obviously reduces lung tissue inflammatory factor synthesis and release, inflammatory cell infiltration and oxidative stress caused by radiation, and obviously reduces lung tissue fibrosis and lung tissue function barrier caused by radiation, the effect of the tectoridin in resisting radiation-induced lung injury is further proved, research and application of the tectoridin are broadened, and the application range of the tectoridin in resisting radiation-induced lung injury is widened. Meanwhile, a new target spot and a new visual field are provided for treating the radiation-induced lung injury.

The invention relates to the technical field of bioengineering, and particularly discloses a construction method and application of a mixed type liver cancer mouse model, pCMV-Cre, pT3-EF1 alphaH-c-Met, pT3-EF1 alphaH-N90-beta-catenin plasmids and pCMV (CAT) T7-SB100 transposase are mixed to prepare an injection, and the injection is injected into a C57BL / 6-MFN1flox / flox mouse at the age of 6 weeks in a caudal vein mode to obtain the mixed type liver cancer mouse model. The construction method of the mixed type liver cancer mouse model is stable, reliable, efficient and easy to implement, and the constructed mixed type liver cancer mouse model can be used for exploring the generation and development mechanism of the mixed type liver cancer and researching treatment targets and can also be used for screening drugs for treating the mixed type liver cancer.

The invention discloses a CAR-T cell for overexpressing H2A. Z as well as a preparation method and application of the CAR-T cell. In particular, the present invention provides a chimeric antigen receptor comprising an H2A. Z gene or a variant having the same function as the H2A. Z gene. The chimeric antigen receptor further comprises a signal peptide, a CLDN18.2-targeted antigen binding structural domain, a hinge region, a transmembrane region, a co-stimulation structural domain and an intracellular signal transduction structural domain. In a C57BL / 6 mouse model inoculated with CLDN18.2 positive tumor cells MC38-CLDN18.2 and KPC, the treatment effect of the CLDN18.2-CAR-T cell for overexpressing the H2AZ.1 gene disclosed by the invention is obviously superior to that of a CLDN18.2-CAR-T control group without overexpressing the H2AZ.1 gene.

The present application relates to the technical field of medicine, especially relates to application of a small molecule compound LZ-09 in preparation of a medicine for treating and / or preventing multiple sclerosis. The present application adopts H2O2 damage OLN-93 cells as a nerve cell oxidative stress model, and the result shows that LZ-09 treatment significantly weakens the cell viability decrease caused by H2O2. The classic EAE model is made by using MOG35-55 to induce C57BL / 6 mice, and it is found that after LZ-09 intervention, the mouse neurological deficit symptom score is significantly reduced, and the disease progression is delayed, and spinal cord tissue HE and LFB staining find that the inflammation infiltration and demyelination are reduced. Therefore, the compound can effectively alleviate the symptoms of multiple sclerosis, can be used as a medicine for treating multiple sclerosis, and has wide development and application prospect.

The invention relates to the field of biological medicines, in particular to a preparation method of a novel black soybean hull extract and application of the black soybean hull extract in preparation of a medicine for treating Alzheimer's disease. The preparation method of the black soybean hull extract does not need toxic organic solvent extraction, is different from only extraction of black soybean hull anthocyanin, can reserve active ingredients of black soybean seed coats to the maximum extent, improves the yield and extraction efficiency of a final compound product, and reduces toxic substances possibly generated in the preparation process. Wild C57BL / 6 mice and disease model APP / Ps1 mice are utilized to research the influence of the black soybean hull extract on the Alzheimer's disease. Compared with disease model mice fed with standard mixed grain feed, the black soybean hull extract is added into diet, so that the learning and memory ability and the movement ability of the disease model mice can be remarkably improved, and the anxiety degree of the disease model mice is reduced. Therefore, the black bean peel extract has a remarkable treatment effect on the Alzheimer's disease. The black bean peel extract has the following advantages in the aspect of treating the Alzheimer's disease: the natural plant extract is non-toxic and has no side effect; raw materials are easily available and the preparation cost is low; the diet intake is convenient and practical. The black soybean hull extract has important scientific significance and application value for treating the Alzheimer's disease.

The invention relates to the technical field of animal model construction, in particular to a construction method and application of an ICI-related myocarditis mouse model closer to clinical application. The ICI-related myocarditis mouse model closer to clinical application is successfully constructed by constructing a liver metastatic tumor model of a C57BL / 6 mouse and then injecting ICIs. The construction method provided by the invention has the advantages of simplicity in operation, low cost and high modeling rate (50-60%), and the ICI-related myocarditis mouse model constructed by the method is closer to clinical application. Meanwhile, the ICI-related myocarditis mouse model obtained by the construction method provided by the invention can also be used for ICI-related myocarditis model mechanism research, ICI-related myocarditis drug screening or ICI-related myocarditis treatment method development and the like.

The invention provides a lung cancer cell LLC-ML2 as well as an establishment method and application thereof. The lung cancer cells are used for highly expressing CD18 molecules, Strc molecules, Cd79a molecules, Amigo2 molecules, Plet1 molecules, Angptl4 molecules and Plac1 molecules; ddx3y, Cbr3, Sox11, Pid1, Kdm5d, Eif2s3y and Capn6 molecules are not expressed or are subjected to low expression. The LLC cell strain is obtained by inoculating common LLC cells to a C57BL / 6 mouse, taking a lung metastatic focus for culture, inoculating primarily cultured metastatic focus cells to the C57BL / 6 again, taking the lung metastatic focus for different clone culture, and screening. Through two times of lung metastatic focus tumorigenesis and screening, compared with LLC cells, the lung cancer cells are shorter in use time for constructing a metastasis model, and the metastasis rate of main organs is higher; an efficient cell model is provided for better researching a tumor invasion and metastasis mechanism.

The present invention belongs to the field of biomedical technology, and specifically relates to the use of spermidine in the preparation of a drug for preventing or treating radiation-induced xerostomia. Aiming at the problems of poor efficacy and many side effects of existing drugs for treating radiation-induced xerostomia, the present invention provides the use of spermidine in the preparation of a drug for preventing or treating radiation-induced xerostomia. The radiation-induced xerostomia occurs in head and neck tumors. The administration method of the spermidine is to feed water 7-10 days before irradiation, and the dosage used is 3 mM-5 mM. The present invention proves that spermidine has a certain therapeutic effect on the xerostomia that occurs in C57BL / 6 mice after irradiation, and can restore the saliva flow rate and the number of aquaporin 5 in the mice, providing a promising treatment method for radiation-induced xerostomia.

The invention belongs to the technical field of medicines, and particularly relates to application of CARNS1 in Parkinson's disease (PD). The research finds that CARNS1 is highly expressed in striatum and nigra brain regions in C57BL / 6 mouse brains, is positioned in dopaminergic neurons in the nigra brain regions, and is down-regulated in MPTP and alpha-syn animal models and MPP + cell models; the nigra region CARNS1 knocks down and aggravates MPTP-induced dyskinesia and neurodegeneration, and the exogenous supplement carnosine can partially reverse phenotypes; the overexpression of the wild type CARNS1 can be used for relieving the neurodegeneration in MPTP and alpha-syn models. The invention clarifies the regulation role of CARNS1 in PD, provides a new perspective for understanding the pathogenesis of PD, and prompts that the CARNS1-carnosine metabolic axis may become an important target for intervening the pathological process of PD.

The invention belongs to the technical field of tumor treatment, and particularly relates to a CRISPR library screening method of genes related to ovarian cancer cell growth, tumor formation and immune escape. The sgRNA library comprises sgRNA which is selected from 80 genes in a MusCK library in a targeting manner. According to the invention, a targeted MusCK library of 922 genes related to the starting, progression and immunoregulation of tumors is used, and a P53- / -Carm1OE Ccne1OE KrasOE mouse ovarian cancer cell line, a C57BL / 6 mouse and a BALB / c-nu mouse are respectively adopted for high-throughput screening, so that the immunoregulation of tumors is realized. A series of confirmed and unverified key genes for high-grade serous ovarian cancer cell growth, tumor formation and immune escape function exertion are successfully screened, and an important theoretical and experimental foundation is laid for finding a novel treatment target of the high-grade serous ovarian cancer; and breakthrough in targeted therapy of high-grade serous ovarian cancer is facilitated.

The invention belongs to the technical field of animal model establishment, and discloses an establishment method and application of a chronic oral ferric citrate induced Parkinson mouse model, C57BL / 6 mice are fed with mouse maintenance food (high-iron feed) added with 2.25% ferric citrate for 22 weeks, and then a 5% ferric citrate solution is used for intragastric administration for 4 weeks. Finally, behavioral evaluation is carried out through behavioral tests such as an open field test, a rotating rod test, a pole climbing test, a holding power test and a Y labyrinth test, and the tests such as the rotating rod test, the pole climbing test and the holding power test show that the PD model mouse has remarkable motor function impairment such as reduction of motor coordination, muscular tension and balance force; open field tests and Y maze show that learning and memory functions of mice are impaired, and cognitive impairments such as anxiety mood occur. Clinical chronic disease conditions of Parkinson's disease are simulated, and the chronic model is more suitable for monitoring early changes and screening early diagnosis indexes of Parkinson's disease; the method has the characteristics that the behavioral disorder can be quantified, and DA energy neuron degeneration loss characteristic lesion is realized.

The invention belongs to the technical field of biological medicines, and particularly relates to application of Forskolin in preparation of a medicine for preventing and treating radioactive intestinal injury. According to the invention, a new effective prevention and treatment target, namely CREB (p-CREB), for the radioactive intestinal injury is found through an Rprm gene knockout (Rprm- / -) C57BL / 6 mouse model, and the prevention and treatment effect of the CREB agonist FSK on the radioactive intestinal injury is verified. FSK has been used in clinical research and has no adverse reaction, which means that FSK has potential to become a clinical medicine for preventing and treating radioactive intestinal injury.

The invention belongs to the technical field of medical experimental animal models, and particularly relates to a stable and high-reproducibility severe acute pancreatitis mouse model construction method, a quantitative evaluation system and application thereof, and the method comprises the following steps: selecting a male C57BL / 6 mouse of 6-8 weeks old, adaptively feeding for one week, and then carrying out model induction; the preparation method comprises the following steps: carrying out intraperitoneal injection on leptofrog at the dosage of 100 mu g / kg once every 1 hour, and continuously injecting for 7 times; within 2 hours after completion of the seventh time of rain frog element injection, lipopolysaccharide is injected into the abdominal cavity, and the dosage is 12 mg / kg; pathological and physiological index evaluation is carried out on the mouse 24 hours after the first time of rain frog element injection, and multi-batch verification experiments prove that the inter-batch fluctuation range of the model constructed by the invention on the death rate, the pathological score, the weight change and other key indexes is controlled within + / -5%, so that the repeatability and comparability of experimental results are ensured.

The invention relates to the technical field of lung adenocarcinoma cell lines, in particular to a mouse Trp53 / Keap1 mutant lung adenocarcinoma cell line (Mus musculus) as well as construction and application of the mouse Trp53 / Keap1 mutant lung adenocarcinoma cell line. The mouse Trp53 / Keap1 mutant lung adenocarcinoma cell line (Mus musculus) constructed by the invention is delivered to the China Center for Type Culture Collection on May 18, 2025, and the preservation number is CCTCC (China Center for Type Culture Collection) NO: C2025163. The cell line is derived from a lung adenocarcinoma model of a C57BL / 6 strain mouse, carries the most common Keap1 mutation in lung adenocarcinoma, is the first known lung adenocarcinoma mouse cell line only carrying Keap1 and Trp53 mutations in the world at present, has the in-vivo tumorigenesis ability of the C57BL / 6 mouse, and fills the blank of the mouse mutant cell line in the level.